Predicting lung fibrosis in post-COVID-19 patients after discharge with follow-up chest CT findings

Rabab Yasin\(^1\)*, Ahmed Abdelhakim Kamel Gomaa\(^2\), Tamer Ghazy\(^3\), Shaimaa Abdelhamid Hassanein\(^1\), Reda Abdel latif Ibrahem\(^4\) and Mohamed Hossameldin Khalifa\(^5\)

**Abstract**

**Background:** Coronavirus disease has spread widely all over the world since the beginning of 2020, and this required rapid adequate management. High-resolution computed tomography (HRCT) has become an initial valuable tool for screening, diagnosis, and assessment of disease severity. This study aimed to assess the clinical, radiographic, and laboratory findings of COVID-19 with HRCT follow-up in discharged patients to predict lung fibrosis after COVID-19 infection in survived patients.

**Results:** This study included two-hundred and ten patients who were tested positive for the novel coronavirus by nasopharyngeal swap, admitted to the hospital, and discharged after recovery. Patients with at least a one-time chest CT scan after discharge were enrolled. According to the presence of fibrosis on follow-up CT after discharge, patients were classified into two groups and assigned as the "non-fibrotic group" (without evident fibrosis) and "fibrotic group" (with evident fibrosis). We compared between these two groups based on the recorded clinical data, patient demographic information (i.e., sex and age), length of stay (LOS) in the hospital, admission to the ICU, laboratory results (peak C-reactive protein [CRP] level, lowest lymphocyte level, serum ferritin, high-sensitivity troponin, D-dimer, administration of steroid), and CT features (CT severity score and CT consolidation/crazy-paving score). CT score includes the CT during the hospital stay with peak opacification and follow-up CT after discharge. The average CT follow-up time after discharge is 41.5 days (range, 20 to 65 days). There was a statistically significant difference between both groups \((p < 0.001)\). Further, a multivariate analysis was performed and found that the age of the patients, initial CT severity score, consolidation/crazy-paving score, and ICU admission were independent risk factors associated with the presence of post-COVID-19 fibrosis \((p<0.05)\). Chest CT severity score shows a sensitivity of 86.1%, a specificity of 78%, and an accuracy of 81.9% at a cutoff point of 10.5.

**Conclusion:** The residual pulmonary fibrosis in COVID-19 survivors after discharge depends on many factors with the patient's age, CT severity, consolidation/crazy-paving scores, and ICU admission as independent risk factors associated with the presence of post-COVID-19 fibrosis.

**Keywords:** COVID-19, Coronavirus infections, Follow-up CT, Lung fibrosis
Background
The novel coronavirus disease (COVID-19) pandemic started in December 2019 in Wuhan, China, and widely spread like wildfire across the globe. It had infected more than 61 million people and killed over 1.4 million people by December 1 as reported by the World Health Organization [1].

High-resolution computed tomography (HRCT) has become a valuable tool for screening, initial diagnosis, and assessment of disease severity [2]. The most commonly reported CT imaging findings for COVID-19 were bilateral peripheral ground-glass patches or consolidations more at basal lung segments [3–5]. Previous studies had discussed the radiological features of the disease at different stages [6–8], but radiological findings after patient discharge and during recovery need to be investigated.

The novel coronavirus SARS-CoV-2 causing COVID-19 disease is genetically similar to other strains of the coronavirus family, which are known as severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). All of them cause pulmonary affection and progress to acute respiratory distress syndrome (ARDS) [9]. Wu et al. [10] reported that residual pulmonary changes could be persistently found years after recovery from SARS. This raises an important question, whether similar late sequelae could also happen with COVID-19 or not.

In China, early reports indicated that 20% of COVID-19 cases have a severe course that requires hospitalization, and quarter of these hospitalized patients need intensive care admission [11]. A recent global literature survey showed that among the hospitalized patients with COVID-19, about one third of cases (33%) develop ARDS, a quarter (26%) require transfer to ICU, and 1/6 (16%) receive invasive mechanical ventilation, and for patients transferred to an ICU, nearly three quarter (75%) have ARDS [12].

Pulmonary fibrosis is a recognized sequelae of ARDS. Its pathogenesis was previously described in other coronavirus infections and was explained by viral-induced lung injury, immune response, and activation of a repair process by fibroproliferation. This repair process can result in the repair of affected lung parenchymal or may lead to pulmonary fibrosis with architectural distortion and irreversible lung changes [13]. So, pulmonary fibrotic changes occur early in the acute stage of infection as an attempt of repair following pulmonary injury. However, it is still early in the process of the disease and requires follow-up to determine if it would resolve with time or result in permanent pulmonary fibrosis [14]. The same changes occur in COVID-19 infection leading to potential increase in the risk of occurrence of pulmonary fibrosis.

Given the huge number of individuals affected by COVID-19, even a less common complication will have major health effects at the population level [15]. To date, about 28 million people have recovered from COVID-19 worldwide after more than 10 months from the start of the pandemic; more concerns about long-term lung changes following infection have evolved, yet no sufficient data is available for COVID-19 patients after discharge. So, it is important to start identifying the possibility of development of pulmonary fibrosis in the survivor population after recovery.

The aim of our study is to assess the clinical, radiographic, and laboratory findings of COVID-19 with HRCT follow-up in discharged patients to predict lung fibrosis after COVID-19 infection.

Methods
This study included two-hundred and ten patients who were tested positive for the novel coronavirus by nasopharyngeal swap, admitted to the hospital, and discharged after recovery. Patients with at least one-time chest CT scan during hospital stay and another follow-up CT after discharge were enrolled in our retrospective study in the period of 1st of August to 1st of December 2020.

The inclusion criteria included the following: (1) confirmed COVID-19 cases by nasopharyngeal swab RT-PCR testing, (2) hospitalized patients, and (3) patients who underwent initial CT during hospitalization and follow-up CT after discharge.

The discharge criterion matched the following conditions: (1) no fever for more than 3 days, (2) relief of dyspnea, (3) improvement in radiological abnormalities on chest X-ray or CT, and (4) two consecutive negative COVID-19 nucleic acid detection at least 24 h apart [16].

There were 149 males and 61 females with male to female distribution of 2.4:1; their age ranged from 18 to 94 years old with a mean age of 53.85±14.84. The study protocol was approved by the local ethics committee. All patients provided a written informed consent.

According to the presence of fibrosis on follow-up CT after discharge, patients were classified into two groups and assigned as the “non-fibrotic group” (without evident fibrosis) and “fibrotic group” (with evident fibrosis).

We compared between these two groups based on the recorded clinical data, patient demographic information (i.e., sex and age), length of stay (LOS) in the hospital, admission to the ICU, laboratory results (peak C-reactive protein [CRP] level, lowest lymphocyte level, serum ferritin, high-sensitivity troponin, D-dimer, administration of steroid), and CT features (CT severity score and CT consolidation/crazy-paving score). CT
score includes the CT during the hospital stay with peak opacification and follow-up CT after discharge. The average CT follow-up time after discharge is 41.5 days (range, 20 to 65 days).

**Image acquisition**
All CT examination was performed using two multidetector CT scanner (Somatom Perspective, Siemens, Germany and Optima CT 540, GE, USA), using the following parameters: tube voltage = 120 kVp, tube current (regulated by automatic dose modulation) 30–75 mAs, pitch=1–1.25mm, matrix = 512 × 512, slice thickness = 5 mm, and FOV = 350 mm × 350 mm.

The patients were in the supine and headfirst position and received scanning with breath held. No contrast was administered. All images were transmitted to the post-processing workstation and reconstructed using high-resolution and conventional algorithms at a slice thickness of 1–1.25 mm.

Three experienced radiologists (20 and 15 years of clinical experience in chest imaging) reviewed all the scans; they were blinded to the patients’ clinical and laboratory data. The final decisions were established by consensus.

**Image analysis**
The initial chest CT was reviewed for each patient, and the CT severity score was estimated for each one of the five lung lobes by calculation of the dissemination of the chest manifestations (opacity), namely the ground-glass opacity (GGO), consolidation, crazy-paving pattern, septal thickening, and pulmonary fibrosis giving score (0–4) for 0, 25, 50, and ≥75% involvement, respectively, with the sum representing the total severity scores for the whole lung (0–20). If a patient had multiple CT examinations during hospitalization, the most severe CT examination during the disease progression was scored.

Previous studies [17, 18] reported that the degree of consolidation and crazy-paving pattern were highly suggestive for the disease progression/peak, so we used the total sum extent of crazy paving and consolidation as an indicator for the disease severity. The severity score for the consolidation and crazy paving was calculated for each lobe using the same criteria (0–4 scores), and the total score for the lungs is the sum of individual lobes (0–20 scores).

Ground-glass opacity (GGO) is defined as an increase in the lung density, but the bronchial vascular bundles are still visible. Consolidation is defined as opacification in which the underlying vasculature was obscured. Fibrosis was defined as parenchymal bands, irregular interfaces (bronchovascular, pleural, or mediastinal), coarse reticular pattern, and traction bronchiectasis [19].

**Statistical analysis**
The data were collected and analyzed by Statistical Package for Social Science (SPSS) version 17.0 on an IBM-compatible computer (SPSS Inc., Chicago, IL, USA). The qualitative data was described as number and percentage and analyzed by using the chi-square test. Quantitative data was described as mean, standard deviation, and range; the t test and Mann-Whitney U test were used to compare normally and not normally distributed quantitative data, respectively.

Binary logistic regression was used to predict the independent risk factors of fibrosis after COVID-19 recovery. The receiver operating characteristic (ROC) curve was used to estimate the accuracy of fibrosis prediction by chest CT severity score. A p value of less than 0.05 was considered significant.

| Table 1 General table characteristics of the studied patients | The studied group, N = 210 |
|-----------------|--------------------------|
| **Age (years)** | Mean ±SD 53.85±14.84 |
|                 | Range 18–94 |
| **Sex**         | Male 149 (71.0%) |
|                 | Female 61 (29.0%) |
| **Severity score** | Mean ±SD 11.23±5.07 |
|                 | Range 1–20 |
| **Consolidation/crazy-paving score** | Mean ±SD 8.89±5.30 |
|                 | Range 0–20 |
| **Length of hospital stay** | Mean ±SD 15.63±16.99 |
|                 | Range 1–170 |
| **ICU admission** | No 158 (75.2%) |
|                 | Yes 52 (24.8%) |
| **Steroid**     | No 34 (16.2%) |
|                 | Yes 176 (83.8%) |
| **High-sensitivity troponin** | Normal 165 (78.6%) |
|                 | High 45 (21.4%) |
| **Ferritin**    | Normal 67 (31.9%) |
|                 | High 143 (68.1%) |
| **Fibrosis on follow-up CT** | No 109 (51.9%) |
|                 | Yes 101 (48.1%) |
Results

This study included two-hundred and ten patients who were tested positive for the novel coronavirus by nasopharyngeal swap, admitted to the hospital, and discharged after recovery. Patients with at least one-time chest CT scan after discharge were enrolled in our retrospective study in the period of 1 August to 1 December 2020.

There were 149 males and 61 females with a male to female distribution of 2.4:1; their age ranged from 18 to 94 years old with a mean age of 53.85±14.84.

Table 1 shows the general characteristics of the studied patients, including patient demographic information, clinical information (admission to the ICU, administration of steroid, and length of stay (LOS) in the hospital), and laboratory studies including the lowest lymphocyte level, C-reactive protein (CRP) level, serum ferritin, high-sensitivity troponin, D-dimer, and radiological findings (CT severity score and CT consolidation/crazy-paving score).

Regarding the peak CT manifestations of COVID-19 pneumonia, it showed bilateral and peripheral distributions in 143 patients (68.1%) with the GGO and crazy-paving appearance as the predominant pattern (153 patients, 72.9%) followed by consolidation (134 patients, 63.8%) and air bronchogram as the common findings (121 patients, 57.6%) while fibrosis was seen in 86 patients (41%) and pleural effusion was seen only in 21 patients (10%).

According to the presence of fibrosis on follow-up CT after discharge, patients were classified into two groups and assigned as the “non-fibrotic group” (without evident fibrosis) and “fibrotic group” (with evident fibrosis).

Table 2 shows the CT characteristic features of the initial/peak CT in both fibrotic and non-fibrotic groups; the number of affected segments was significantly higher in the fibrotic group ($p<0.001$).

There were no significant differences between both groups as regards the distribution and location of the lesions. Pure GGO was statistically higher in the non-fibrotic group, while pure consolidation or GGO with
consolidation (Figs. 1 and 2), crazy paving, air bronchoogram, and fibrotic changes (Fig. 3) were significantly higher in fibrotic groups ($p<0.001$).

The demographic and clinical data of the two groups are comparatively presented in Table 3; there was a statistically significant difference between both groups as regards patient’s age (Figs. 4, 5, and 6) with no statistically significant difference regarding sex. Patients in the fibrotic group were older than those in the non-fibrotic group (mean age, $58.81\pm14.82$ vs $49.26\pm13.36$ years) ($p<0.001$).

Regarding ICU admission (Figs. 7 and 8), steroid therapy, and length of stay (LOS) in the hospital, there was

---

**Fig. 1** Fifty-five-year-old female: she has DM, HTN, and IHD; peak CT severity score 12; consolidation/crazy-paving score 10. She was admitted to the ICU; laboratory results show lymphopenia, high CRP, D-dimer, serum ferritin, and high-sensitivity troponin. Steroid was given; length of stay during hospitalization is 15 days. Peak CT during admission (a–d) showed bilateral consolidation patches more at the lower lobes with a crazy-paving appearance (arrows). Follow-up CT 3 weeks after discharge (e–h) shows lung fibrosis with a coarse reticular pattern mainly dependent (arrows).

**Fig. 2** Fifty-nine-year-old male: he has DM; peak CT severity score 10; consolidation/crazy-paving score 8. No ICU admission; laboratory results show lymphopenia, high CRP, D-dimer, and serum ferritin. Steroid was given; length of stay during hospitalization is 10 days. Peak CT (a–d) shows bilateral peripheral consolidation patches mainly in the lower lobes (arrows). Follow-up CT 2 months after discharge (e–h) shows residual fibrosis with parenchymal bands, coarse reticular pattern (arrows), and atoll sign (black arrow in g).
also a statistically significant difference between both groups ($p < 0.001$). The LOS in the fibrotic group was longer than that in the non-fibrotic group ($23.26 \pm 20.89$ vs $8.56 \pm 7.03$ days). The percentage of ICU admission in the fibrotic group was higher than in the non-fibrotic group ($44.6\%$ vs $6.6\%$).

In comparison with both groups in laboratory studies including lowest lymphocyte level, C-reactive protein (CRP) level, serum ferritin, high-sensitivity troponin, and d-dimer, there was a statistically significant difference between both groups ($p < 0.001$) with higher serum levels detected among the fibrotic group.

As regards both CT severity score and consolidation/crazy-paving score calculated from the initial CT during hospitalization, there was a statistically significant difference between the two groups ($p < 0.001$) with higher values observed among the fibrotic group compared to the non-fibrotic group (Fig. 9).

Based on these variables, a further multivariate analysis using the forward method was performed, and it was found that the age of the patients, initial CT severity score, consolidation/crazy-paving score, and ICU admission were independent risk factors associated with the presence of post-COVID-19 fibrosis ($p < 0.05$, Table 4).

Analysis of the ROC curve for independent factors for the prediction of post-COVID-19 fibrosis is shown in Fig. 10 and Table 5; the highest area under the curve (AUC) of 0.94 was for chest CT severity score showing a sensitivity of 86.1%, a specificity of 78% and accuracy of 81.9% at a cutoff point of 10.5.

**Discussion**

Over the past months, HRCT had participated effectively in the diagnosis of COVID-19 and assessment of disease severity. The major imaging features of COVID-19 pneumonia have been discussed in detail in many publications [20]. However, the post-recovery outcome of the disease and its long-term effects on lung parenchyma remain unanswered questions.

The previous experience with SARS and MERS showed that follow-up CT is recommended in individuals recovering from COVID-19 to evaluate which group of patients is more likely to develop pulmonary fibrosis [21].

In this study, we aimed to evaluate the radiological findings on follow-up HRCT of patients recovered from COVID-19 and identify the possibility of pulmonary fibrosis in discharged patients after treatment.

At the current study, patients were classified into two groups according to the presence of fibrosis on follow-up CT after discharge: "fibrotic group" (with evident fibrosis) and "non-fibrotic group" (without evident fibrosis). Out of 210 patients, 101 patients
(48.1%) showed fibrosis on follow-up CT while 109 patients (51.9%) had no evident fibrosis.

Our results showed a statistically significant difference between the two groups regarding the patient’s age where patients in the fibrotic group were significantly older than those in the non-fibrotic group indicating that elderly patients are more liable to develop fibrosis following COVID-19.

In line with our study, Yu et al. [22] found that patients who developed fibrosis on follow-up after discharge were older than those without fibrosis, suggesting that fibrosis was more common in elderly patients, similar to SARS. They stated that patients with fibrosis had a longer length of stay in the hospital with a higher rate of ICU admission and a higher level of CRP than those without fibrosis; they also reported that patient with fibrosis had received more pulsed steroid therapy and antiviral therapy and for a longer period compared with patients without fibrosis; thus, these clinical parameters during acute disease may help in the prediction of the risk of developing pulmonary fibrosis after discharge.

Similarly, our results showed that patients in the fibrotic group showed a longer length of stay in the hospital and a longer duration of ICU admission and steroid therapy ($p < 0.001$). In comparison with both groups regarding the laboratory results including the

| Table 3 Comparison between COVID-19 patients with and without evidence of fibrosis. Non-fibrotic group ($n = 109$); fibrotic group ($n = 101$) |
|-----------------|-----------------|-----------------|-----------------|------------------|
| The studied group, $N = 210$ | Non fibrotic, $N = 109$ | Fibrotic, $N = 101$ | Test | $p$ value |
| Age (years) | | |
| Mean ±SD | 49.26±13.36 | 58.81±14.82 | $t$ test | <0.001 |
| Range | 18–76 | 24–94 | 4.91 | |
| Sex | | |
| Male | 76 (69.7%) | 73 (72.3%) | $X^2$ | 0.65 |
| Female | 33 (30.3%) | 28 (27.7%) | | |
| Severity score | | |
| Mean ±SD | 7.55±3.32 | 15.20±3.34 | $U$ | <0.001 |
| Range | 1–14 | 9–20 | 11.09 | |
| Consolidation/crazy-paving score | | |
| Mean ±SD | 5.42±3.55 | 12.63±4.22 | $U$ | <0.001 |
| Range | 0–15 | 5–20 | 10.06 | |
| Lymphopenia | | |
| Mean ±SD | 64 (58.7%) | 79 (78.2%) | $X^2$ | 0.002 |
| Range | 5–20 | 5–20 | 9.2 | |
| Elevated high-sensitivity troponin | | |
| Mean ±SD | 17 (15.6%) | 28 (27.7%) | $X^2$ | 0.03 |
| Range | 5–20 | 5–20 | 4.6 | |
| High ferritin levels | | |
| Mean ±SD | 62 (56.9%) | 81 (80.2%) | $X^2$ | <0.001 |
| Range | 20–120 | 20–120 | 13.1 | |
| Elevated CRP | | |
| Mean ±SD | 90 (82.6%) | 95 (94.1%) | $X^2$ | 0.01 |
| Range | 66 | 66 | 6.6 | |
| Elevated D-dimer | | |
| Mean ±SD | 87 (79.8%) | 96 (95.0%) | $X^2$ | 0.001 |
| Range | 5–200 | 5–200 | 10.9 | |
| Length of hospital stay | | |
| Mean ±SD | 8.56±7.03 | 23.26±20.89 | $U$ | <0.001 |
| Range | 1–37 | 2–170 | 8.26 | |
| ICU admission | | |
| No | 102 (93.6%) | 56 (55.4%) | $X^2$ | <0.001 |
| Yes | 7 (6.4%) | 45 (44.6%) | 40.9 | |
| Steroid | | |
| No | 27 (24.8%) | 7 (6.9%) | $X^2$ | <0.001 |
| Yes | 82 (75.2%) | 94 (93.1%) | 12.3 | |
lowest lymphocytic level, CRP level, serum ferritin, high-sensitivity troponin, and D-dimer levels, there were statistically significant differences between both groups (\( p < 0.001 \)) with higher serum levels detected among patients in the fibrotic group suggesting that higher inflammatory markers are more associated with developing fibrosis.

Shi et al. [23] found that on COVID-19 patients, cardiac troponin is a prognostic marker with a strong association with mortality observed in the currently

---

**Fig. 4** Sixty-four-year-old male: he has DM and HTN; peak CT severity score 17; consolidation/crazy-paving score 11. No ICU admission; laboratory results showed lymphopenia, high CRP, D-dimer, and serum ferritin. Steroid was given; length of stay during hospitalization is 20 days. Peak CT (a–d) showed GGO with interstitial thickening giving a crazy-paving appearance (arrows). Follow-up CT 45 days after discharge (e–h) showed almost resolution of the previous with residual fibrosis with parenchymal bands, coarse reticular pattern, and mild traction bronchiectasis at the anterior segment of the right upper lobe and lateral segment of the right middle lobe (arrows).

---

**Fig. 5** Thirty-year-old female: she has no previous medical illness; CT severity score 15; consolidation/crazy-paving score 10. No ICU admission; laboratory results showed normal lymphocyte and serum ferritin, high CRP, D-dimer. Steroid was given; length of stay during hospitalization is 14 days. Peak CT during admission (a–d) showed bilateral central and peripheral GGO mainly in the upper lobes, associated with lung fibrosis with parenchymal bands and coarse reticular pattern (arrows). Follow-up CT 2 months after discharge (e–h) showed total resolution of the previous lung changes.
available reports of patients hospitalized with COVID-19, with some evidence suggesting cardiac troponin T/I even as an independent predictor of mortality.

At the current study, higher values for CT severity score and consolidation/crazy-paving score on the initial CT were found in the fibrotic group compared to the non-fibrotic group suggesting that patients with severe disease are more liable to fibrosis after discharge.

In the same context, Wei et al. [24] included 59 patients who were treated for COVID-19 pneumonia in a multi-center study and had a follow-up CT within 1 month after being discharged from four hospitals in

---

**Fig. 6** Twenty-five-year-old male: he has no previous medical illness; CT severity score 14; consolidation/crazy-paving score 12. No ICU admission; laboratory results show lymphopenia, high CRP, D-dimer, and serum ferritin. Steroid was given; length of stay during hospitalization is 10 days. Peak CT during admission (a–d) showed bilateral central and peripheral consolidation patches mainly in the lower lobes with GGO and a crazy-paving pattern (arrows). Follow-up CT 2 months after discharge (e–h) showed total resolution of the previous lung changes.

---

**Fig. 7** Fifty-five-year-old male: he has DM, HTN, and IHD; peak CT severity score 16; consolidation/crazy-paving score 14. He was admitted to the ICU; laboratory results showed lymphopenia, high CRP, D-dimer, normal serum ferritin, and sensitivity troponin. Steroid was given; length of stay during hospitalization is 30 days. Peak CT during admission (a–d) showed bilateral consolidation patches more peripheral and at the lower lobes with a crazy-paving appearance. Follow-up CT 3 weeks after discharge (e–h) showed lung fibrosis with parenchymal bands, coarse reticular pattern, irregular interface, and mild traction bronchiectasis at the anterior segments of both upper lobes and the medial segment of the right middle lobe.
China; their study showed that 39% of patients had residual fibrosis while 61% had no evidence of fibrosis on HRCT. They found that elderly patients had a higher chance of developing fibrosis, and patients who developed fibrosis had a higher CT score, higher ICU admission, and higher C-reactive protein. They also cited previous work by Antonio et al. [19] in studying severe cases of SARS who stated that early lung fibrosis rate reaches as high as 62% in SARS. COVID-19 showed a lower rate of fibrosis than SARS. In addition, SARS causes severe lung parenchymal damage than COVID-19.

Likewise, Das et al. [25] stated that 33% of patients with MERS show lung fibrosis on follow-up CT. These
patients were older in age, had a longer duration of ICU admission, and had more severe lung involvement in the acute stage of the disease.

Additionally, we performed multivariate analysis for predictors of post-COVID-19 fibrosis, and we found that among these previous significant variables, patient's age, initial CT severity score, consolidation/crazy-paving score, and ICU admission were independent risk factors associated with post-COVID-19 fibrosis \((p<0.05, \text{Table 4})\). Further analysis of the ROC curve for independent factors was done and showed the highest AUC for chest CT severity score reflecting a good predictive value for post-COVID-19 fibrosis with a sensitivity of 86.1% and a specificity of 78% at a cutoff point of 10.5.

Yu et al. [22] compared the imaging features between a group of patients with fibrosis and without fibrosis regarding the initial CT; they found that more patients in the fibrosis group had interstitial thickening, coarse

Table 4 Multivariate regression analysis for independent risk factors for prediction of post-COVID-19 fibrosis

| Risk Factor                  | SE  | Wald \(X^2\) | \(p\) value | Odds ratio (95% CI) |
|------------------------------|-----|--------------|-------------|---------------------|
| Age (years)                  | 0.02| 9.39         | 0.002       | 3.37 (0.76–14.55)   |
| Severity score               | 0.12| 8.95         | 0.003       | 2.38 (1.18–4.41)    |
| Consolidation/crazy-paving score | 0.11| 1.93         | 0.04        | 1.91 (0.63–4.35)    |
| Lymphocytes                  | 0.53| 0.49         | 0.49        | 0.70 (0.25–1.96)    |
| High-sensitivity troponin    | 0.66| 0.29         | 0.59        | 0.90 (0.35–2.42)    |
| Ferritin                     | 0.52| 0.40         | 0.84        | 0.90 (0.35–2.42)    |
| CRP                          | 0.06| 0.67         | 0.41        | 1.12 (0.38–3.19)    |
| D-dimer                      | 0.10| 2.59         | 0.05        | 1.98 (1.01–10.19)   |
| Length of hospital stay      | 0.69| 7.82         | 0.005       | 6.77 (1.77–25.88)   |
| ICU admission                | 0.74| 0.16         | 0.69        | 1.01 (0.24–4.28)    |

Fig. 10 ROC curve for age, chest CT severity, and consolidation/crazy-paving scores as a predictor for post-COVID-19 fibrosis to detect the sensitivity and specificity of these factors
reticulations, and subpleural/parenchymal bands on the initial CT. Also, more lung segments were involved on the initial CT in patients in the fibrosis group than in the non-fibrosis group. They suggested that these findings on the initial CT as interstitial thickening, reticulations, and parenchymal bands might be predictors of pulmonary fibrosis in recovered patients since they have similar pathogenesis.

This was matching with our results that showed more lung segment affection on the initial CT in the fibrotic group compared to the non-fibrotic group \((p<0.001)\). Pure GGO was statistically higher in the non-fibrotic group, while pure consolidation or GGO with consolidation, crazy paving, air bronchogram, and fibrotic changes were significantly higher in the fibrotic groups \((p<0.001)\).

At the current study, follow-up CT after discharge was performed at an average time of 41.5 days (range 20–65 days) after discharge, and it showed persistent parenchymal abnormalities with fibrotic changes in 48.1% of patients while 51.9% of patients had no residual parenchymal changes or fibrosis.

These results were in accordance with the findings reported by Liu et al. \[26\] who performed a 3-week follow-up study to determine the cumulative percentage of complete radiological resolution of pulmonary changes in discharged patients recovering from COVID-19. They stated that in 53% of patients, the pulmonary changes were completely absorbed at the 3rd week after discharge, reflecting that pulmonary damage induced by COVID-19 could be potentially repaired without permanent sequelae. However, more than 40% of patients at the 3rd week radiological follow-up showed residual parenchymal abnormalities, including GGO and fibrous parenchymal bands. In their study, younger age was associated with more complete radiological resolution.

Zaho et al. \[27\] in a multi-center cohort study found that residual pulmonary abnormalities and abnormal CT scores persisted for 3 months after discharge in 70.91% of COVID-19 survivors. Bilateral lung involvement was still found in 23.6% of patients and in about half of patients (54.55%); 1–3 lung segments were involved. Typical parenchymal features were almost resolved, but evidence of fibrosis was observed. The most common CT feature found on the latest follow-up was interstitial thickening (27.27%).

The current study has limitations to be acknowledged. First, small sample size relative to the disease burden. Therefore, studies in larger samples should be considered. Second, fibrosis was not confirmed by histopathology even though imaging manifestations were diagnostic. Third, follow-up time was relatively short, and it is unknown whether these pulmonary changes will resolve on further follow-up or permanently remain, so long-term follow-up studies are recommended for further research.

**Conclusion**

The residual pulmonary fibrosis in COVID-19 survivors after discharge depends on many factors with patient’s age, CT severity, consolidation/crazy-paving scores, and ICU admission were independent risk factors associated with the presence of post-COVID-19 fibrosis.

**Abbreviation**

HRCT: High-resolution computed tomography; SARS-CoV: Severe acute respiratory syndrome coronavirus; MERS-CoV: Middle East respiratory syndrome coronavirus; ARDS: Acute respiratory distress syndrome; ICU: Intensive care admission; LOS: Length of stay; RT-PCR: Reverse transcriptase polymerase chain reaction; CRP: C-reactive protein; GGO: Ground glass opacity; CT: Computerized tomography; SPSS: Statistical Package for Social Science; ROC: Receiver operating characteristic; AUC: Area under the curve

**Acknowledgements**

We would like to thank all the people who helped us in this work including the clinicians and technicians.

**Authors’ contributions**

R Yasin, A A K Gomaa, T Ghazy, S A Hassanein, R A L Ibrahim, and M H Khalifa equal sharing between authors as regards writing of the manuscript, the collection and analysis of the data, and revision of the final manuscript. All authors have read and approved the final manuscript.

**Funding**

Self-funding.

---

**Table 5** Accuracy of independent factors for prediction of fibrosis

|               | Age  | Severity score | Consolidation | ICU admission |
|---------------|------|----------------|---------------|--------------|
| AUC           | 0.68 | 0.94           | 0.90          | –            |
| \(p\) value   | <0.001 | <0.001       | <0.001         | –            |
| 95% CI        | 0.61–0.76 | 0.92–0.97 | 0.86–0.94     | –            |
| Cutoff point  | 51.5 | 10.5           | 7.5           | –            |
| Sensitivity   | 73.3% | 86.1%          | 86.1%         | 44.6%        |
| Specificity   | 59.6% | 78%            | 75.2%         | 93.6%        |
| PPV           | 62.7% | 78.4%          | 76.3%         | 86.5%        |
| NPV           | 70.7% | 85.9%          | 85.4%         | 64.6%        |
| Accuracy      | 66.2% | 81.9%          | 80.5%         | 70.0%        |
Availability of data and materials
All data and materials are available.

Declarations

Ethics approval and consent to participate
The study protocol was approved by the local Ethics Committee (HSC Ethical Committee). All study procedures were performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. No available ethics committee’s reference number.
A written consent was taken from all patients prior to the study to be included in our study.

Consent for publication
A written consent was taken from all patients prior to the study for publication.

Competing interests
The authors declare that they have no competing interests.

Author details
1Faculty of Medicine, Menoufia University, Menoufia, Egypt. 2Giza Chest Hospital, Giza, Egypt. 3Cardiology Department, Menoufia University, Menoufia, Egypt. 4Public Health and Community Medicine Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt. 5Department of Radiology, Faculty of Medicine, University of Alexandria, Alexandria, Egypt.

Received: 31 December 2020 Accepted: 14 April 2021
Published online: 03 May 2021

References

1. World Health Organization. Weekly epidemiological update - 1 December 2020. Available from:https://www.who.int/docs/default-source/coronaviruse/situation-reports/20201201_weekly_epi_update_16.pdf.

2. Pan Y, Guan H, Zhou S, Wang Y, Li Q, Zhu T, Hu Q, Xia L. (2020) Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China. Eur Radiol 30(6):3306–3309. https://doi.org/10.1007/s00330-020-06731-x

3. Lin X, Gong Z, Xiao Z, Xiong J, Fan B, Liu J. (2020) Novel coronavirus pneumonia outbreak in 2019: computed tomographic findings in two cases. Korean J Radiol 21(3):365–368. https://doi.org/10.3348/kjr.2020.00787

4. Caruso D, Zerunian M, Polici M, Pucciarelli F, Polidori T, Rucci C, Guido G, Bracci B, de Dominics C, Laghi A. (2020) Chest CT features of COVID-19 in Italy. Radiology 296(2):E79–E85. https://doi.org/10.1148/radiol.2020201237

5. Frazier JB. (2020) Chest CT and coronavirus disease (COVID-19): a more complete review. AJR Am J Roentgenol 215(3):W35. https://doi.org/10.2214/AJR.20.23428

6. Shi H, Han X, Jiang N, Cao Y, Alwaldi O, Gu J, Fan Y, Zheng C. (2020) Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis 20(4):425–434. https://doi.org/10.1016/S1473-3099(20)30086-4

7. Pan F, Ye T, Sun P, Gui S, Li B, Li, Zheng D, Wang J, Hesketh RL, Yang L, Zheng C. (2020) Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19). Radiology 295(3):715–721. https://doi.org/10.1148/radiol.2020200370

8. Wang Y, Dong C, Hu Y, Li C, Ren G, Zhang X, Shi H, Zhou M. (2020) Temporal changes of CT findings in 90 patients with COVID-19 pneumonia: a longitudinal study. Radiology 296(2):E55–E64. https://doi.org/10.1148/radiol.2020200483

9. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W. (2019) Novel Coronavirus Investigating and Research Team (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382(8):727–733. https://doi.org/10.1056/NEJMoa2001071

10. Wu X, Dong D, Ma D et al (2016) Thin-section computed tomography manifestations during convalescence and long-term follow-up of patients with severe acute respiratory syndrome (SARS). Med Sci Monit 22:2793–2799. https://doi.org/10.12659/MSM.896985

11. Wu Z, McGooog JM (2020) Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 323(13):1239–1242. https://doi.org/10.1001/jama.2020.264 8

12. Tzotzos SJ, Fischer B, Fischer H, Zeitlinger M (2020) Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey. Crit Care 24(1):516. https://doi.org/10.1186/s13054-020-03240-7

13. Ojo AS, Babgoun SA, Williams OT et al (2020) Pulmonary fibrosis in COVID-19 survivors: predictive factors and risk reduction strategies. Pulm Med 2020: 6175964

14. Ye Z, Zhang Y, Wang Y, Huang Z, Song B. (2020) Chest CT manifestations of the new coronavirus disease 2019 (COVID-19): a pictorial review. Eur Radiol 30(3):4381–4389. https://doi.org/10.1007/s00330-020-06801-0

15. Spagnolo P, Balestro E, Aliberti S, Coccozzi E, Biondini D, Casa GD, Sverzellati N, Maher TM (2020) Pulmonary fibrosis secondary to COVID-19: a call to arms? Lancet Respir Med (8):750–752. https://doi.org/10.1016/ j.lucr.2020.08.008

16. Wei P (2020) Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7). Chin Med J 133(9):1087–1095

17. Lyu P, Liu X, Zhang R et al (2020) The performance of chest CT in evaluating the clinical severity of COVID-19 pneumonia: identifying critical cases based on CT characteristics. Invest Radiol 55(7):412–421

18. Chen C, Yu N, Cai S, Zhou J, Sheng J, Liu K, Zhou H, Guo Y, Niu G (2020) Quantitative computed tomography analysis for stratifying the severity of coronavirus disease 2019. J Pharm Anal 10(2):123–129. https://doi.org/10.1016/j.jph.2020.03.004

19. Antonio GE, Wong KT, Hui DS et al (2020) Thin-section CT in patients with severe acute respiratory syndrome following hospital discharge: preliminary experience. Radiology 228(3):810–813. https://doi.org/10.1148/radiol.228303 0126

20. Salehi S, Abadi A, Balakrishnan S, Gholamrezaeheid A (2020) Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients. AJR Am J Roentgenol 215(1):87–93. https://doi.org/10.2214/AJR.2 0.23034

21. Hosseiny M, Kooraki S, Gholamrezaeheid A, Reddy S, Myers L (2020) Radiological perspective of coronavirus disease 2019 (COVID-19): lessons from severe acute respiratory syndrome and Middle East respiratory syndrome. AJR Am J Roentgenol 214(5):1078–1082. https://doi.org/10.2214/AJR.20.22 22

22. Yu M, Liu Y, Xu D, Zhang R, Lan L, Xu H (2020) Prediction of the development of pulmonary fibrosis using serial thin-section CT and clinical features in patients discharged after treatment for COVID-19 pneumonia. Korean J Radiol 21(6):746–755. https://doi.org/10.3348/kjr.2020.0215

23. Shi S, Qin M, Shent et al (2020) Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 5(7):802–810

24. Wei J, Yang H, Le P, Fan B, Qiu Y, Zeng B, Yu P, Lv J, Jilin Y, Wai C. (2020) Analysis of thin-section CT in patients with coronavirus disease (COVID-19) after hospital discharge. J Xray Sci Technol 28(3):383–389. https://doi.org/10.3333/XST-200685

25. Das KM, Lee EY, Singh R, Enani MA, al Dossari K, van Gorkom K, Larsson SG, Langer RD (2017) Follow-up chest radiographic findings in patients with severe acute respiratory syndrome and Middle East respiratory syndrome. AJR Am J Roentgenol 218(6):1385–1390. https://doi.org/10.2214/AJR.16.13185

26. Hosseiny M, Kooraki S, Gholamrezaeheid A, Reddy S, Myers L (2020) Radiological perspective of coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients. AJR Am J Roentgenol 215(1):87–93. https://doi.org/10.2214/AJR.2 0.23034

27. Zhao YM, Shang YM, Song WB, Li QQ, Xie H, Xu QF, Jia JL, Li LM, Mao HL, Zhou XM, Luo H, Gao YF, Xu AG (2020) Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. JClinicalMedicine 25:100463. https://doi.org/1 0.3390/jcm.25.11.10600460

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.